AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32861819
Drug: No radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No radiation therapy boost (641 patients, 59.2%)
Trial: 32472958
Drug: Dexamethasone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (16 mg intravenously at start of surgery)
Trial: 32472958
Drug: Control (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (4 ml saline)
Trial: 36124494
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (low dose 0.01 mg and high dose 0.1 mg)
Trial: 32270179
Drug: Insufficient 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insufficient 25(OH)D (<32 ng/mL)
Trial: 35413905
Drug: Intraperitoneal normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal normal saline instillation (INSI) of 15 mL/kg body weight
Trial: 35413905
Drug: Conventional combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional combination of open laparoscopic trocar valves with gentle abdominal pressure
Trial: 33539742
Drug: Standard combined-modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combined-modality treatment (2 + 2 regimen followed by 30 Gy involved-field radiotherapy)
Trial: 33539742
Drug: PET4-guided treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET4-guided treatment (2 + 2 regimen followed by 30 Gy of involved-node radiotherapy only if PET positive)
Trial: 33539742
Drug: Standard combined-modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combined-modality treatment
Trial: 33539742
Drug: PET4-guided treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET4-guided treatment
Trial: 36267888
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies (CT)
Trial: 32866432
Drug: KRd regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRd regimen (36 mg/m2 of intravenous carfilzomib, 25 mg of oral lenalidomide, 40 mg of oral dexamethasone)
Trial: 32866432
Drug: VRd regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRd regimen (1.3 mg/m2 of bortezomib, 25 mg of oral lenalidomide, 20 mg of oral dexamethasone)
Trial: 35528160
Drug: bismuth quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bismuth quadruple therapy (BQT)
Trial: 35315909
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy for 6 weeks
Trial: 37098453
Drug: Clindamycin gel
RxNorm normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin gel
Trial: 35181350
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Con)
Trial: 32510696
Drug: 750 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/kg/day of placebo-control
Trial: 33006975
Drug: GARCH models
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GARCH models with innovations following the compound distributions
Trial: 35345897
Drug: Robotic self-training
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic self-training (ReoGo-J) plus conventional therapy (robotic therapy)
Trial: 35345897
Drug: Conventional self-training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional self-training plus conventional therapy (control)
Trial: 35851754
Drug: Telitacicept 240
RxNorm normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telitacicept 240 mg every week for 46 times after plasma exchange
Trial: 34504196
Drug: Oral rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral rifaximin (550 mg twice daily for 7-10 or 14-21 days preoperatively and 7 days postoperatively)
Trial: 34504196
Drug: Oral rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral rifaximin
Trial: 35475907
Drug: 80 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 µg dasiglucagon (D80)
Trial: 35475907
Drug: 120 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 µg dasiglucagon (D120)
Trial: 33629506
Drug: Caloric restriction
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric restriction diet with fiber supplementation (10 g day-1 inulin + 10 g day-1 resistant maltodextrin)
Trial: 33185050
Drug: 40 mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m² PLD (experimental arm)
Trial: 33185050
Drug: 50 mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m² PLD (standard arm)
Trial: 32972635
Drug: 5% Pueraria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Pueraria mirifica gel
Trial: 35212470
Drug: Drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug use
Trial: 35710599
Drug: Liraglutide 3
RxNorm normalized name: liraglutide 3.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3 mg (LIRA 3 mg)
Trial: 34499672
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg/day)
Trial: 33625251
Drug: Drug targets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug targets identified
Trial: 34694880
Drug: Ruxolitinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (20 mg)
Trial: 34694880
Drug: Artemether-Lumefantrine (80/480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-Lumefantrine (80/480 mg)
Trial: 32412683
Drug: Tertiary-hospital specialist
RxNorm normalized name: Prednisolone tertiary butylacetate
DrugBank: Prednisolone tebutate (DB14632)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tertiary-hospital specialist allergy clinic (CC)
Trial: 36073634
Drug: Intravenous nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicorandil (6 mg bolus followed by 6 mg/h infusion)
Trial: 32555148
Drug: Mixed Meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed Meal (MM) - 120 mL, 523 kJ (125 kcal) four times/day for 14 days
Trial: 32555148
Drug: Electrolyte Solution
RxNorm normalized name: electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte Solution (ES) - 50 kJ (12 kcal) four times/day for 14 days
Trial: 32365097
Drug: Astodrimer 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astodrimer 0.5% Gel
Trial: 32365097
Drug: Astodrimer 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astodrimer 3% Gel
Trial: 36147650
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control group (maintained usual daily routines for 12 weeks)
Trial: 36809247
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed treatment
Trial: 35786002
Drug: Tenecteplase (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (exact dosage not specified)
Trial: 33835016
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (4 mg pridinol mesylate)
Trial: 35783246
Drug: Anti-inflammatory treatment
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory treatment
Trial: 33855195
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 12 weeks
Trial: 35233755
Drug: Trastuzumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab + chemotherapy
Trial: 36482326
Drug: Ivermectin plus
RxNorm normalized name: clorsulon / ivermectin Injectable Solution [Ivermax Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin plus acetaminophen
Trial: 35242882
Drug: C. lacerata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. lacerata (500 mg/capsule) for 12 weeks
Trial: 33681744
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol
Trial: 33556391
Drug: Large portion
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large portion (200 g) consumed at home
Trial: 33556391
Drug: Small portion
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small portion (100 g) consumed at home
Trial: 33556391
Drug: Large portion
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large portion (200 g) consumed in laboratory
Trial: 33556391
Drug: Small portion
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small portion (100 g) consumed in laboratory
Trial: 33482315
Drug: Ammoxetine 2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ammoxetine 2.5, 7.5, 15, 30, 45, 65, 100 mg (single-dose)
Trial: 33482315
Drug: Ammoxetine 15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ammoxetine 15, 30, 45 mg (multiple-dose for 8 days)
Trial: 33482315
Drug: Placebo (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single-dose and multiple-dose)
Trial: 34221032
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene regimen (OHR) including bioavailable stannous fluoride dentifrice, oscillating‐rotating electric toothbrush, cetylpyridinium chloride rinse, and floss
Trial: 34990712
Drug: ABCC1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABCC1 inhibitor probenecid
Trial: 35555189
Drug: Caffeine (CAF:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF: 400 mg/day + 5 g/day of maltodextrin)
Trial: 35555189
Drug: Creatine Nitrate
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine Nitrate + Caffeine (CN+CAF: 5 g/day of creatine nitrate + 400 mg/day of caffeine)
Trial: 35555189
Drug: Placebo (PL:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL: 5.4 g/day of maltodextrin)
Trial: 36252718
Drug: Dexamethasone 24
RxNorm normalized name: dexAMETHasone 24 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 24 mg IV (perioperatively)
Trial: 35366574
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg AZ-009
Trial: 35130086
Drug: Epidural Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural Morphine (5 mg) and Bupivacaine (0.25%, 2 mL)
Trial: 33975325
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein (HP) diet (1.5 g protein/kg body weight)
Trial: 33975325
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein (NP) diet (0.8 g protein/kg body weight)
Trial: 35382844
Drug: Placebo infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions followed by ATI
Trial: 35382844
Drug: Dual long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual long-acting bNAbs infusions
Trial: 33717406
Drug: Vigabatrin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin therapy
Trial: 39466816
Drug: Azithromycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (single dose)
Trial: 34462986
Drug: Radiomics model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiomics model based on T2WI + DWI (combination)
Trial: 33595427
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine cream applied perianally for 10 minutes (group 1)
Trial: 33595427
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally for 10 minutes (group 2)
Trial: 33595427
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally for 20 minutes (group 3)
Trial: 33595427
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally and internally for 10 minutes (group 4)
Trial: 33595427
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally and internally for 20 minutes (group 5)
Trial: 33595427
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally and internally for 10 minutes (group 6)
Trial: 34782430
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccine targeting tumor blood vessel antigens with immediate dasatinib (Arm B)
Trial: 34782430
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccine targeting tumor blood vessel antigens with delayed dasatinib (Arm A)
Trial: 35347874
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) for MDD
Trial: 32179446
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) with 4x TC, interval debulking surgery (IDS), 4x TC
Trial: 32378422
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral melatonin supplementation
Trial: 33864989
Drug: MISSION‐CJ (wraparound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MISSION‐CJ (wraparound treatment)
Trial: 32981534
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation and LAI antipsychotic medication
Trial: 34284802
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus behaviour change therapy
Trial: 35585981
Drug: Normothermic machine
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normothermic machine perfusion (NMP) with oxygenated banked red blood cell (RBC) based solution for 1h at 36°C
Trial: 35230884
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin (40 mg/m2)
Trial: 35230884
Drug: 3-weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weekly cisplatin (100 mg/m2)
Trial: 39141622
Drug: Sleep Restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep Restriction Therapy (SRT)
Trial: 33110130
Drug: Atropine treatment
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine treatment after 3 and 6 months
Trial: 34506986
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (15 mg every 6 hours)
Trial: 33792832
Drug: Placebo, orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally three times daily
Trial: 35411402
Drug: Remote antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote antibiotic stewardship program (ASP)
Trial: 33989812
Drug: Nebulized low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized low molecular weight heparin (1 mg/kg) with albuterol (2.5 mg) every 20 min for 10 min
Trial: 32183861
Drug: Various intravenous
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various intravenous iron preparations
Trial: 37078188
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTI)
Trial: 33784989
Drug: Dienogest 2
RxNorm normalized name: dienogest 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 2 mg/d for 3 months
Trial: 32000598
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of 10mg/ml triamcinolone acetate (CS)
Trial: 35122992
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg wheat flour for 4 weeks)
Trial: 34642366
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intermittent radiation treatment (iRT, [Formula: see text] Gy [Formula: see text] 1 every 6 weeks)
Trial: 34642366
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose hypofractionated stereotactic radiotherapy (HFSRT, [Formula: see text] Gy [Formula: see text] 5 in daily fractions)
Trial: 33549029
Drug: Argatroban 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban 0.5 mg/mL
Trial: 33549029
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) 1,000 U/mL
Trial: 35289096
Drug: Poor communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor communication with good treatment outcome
Trial: 35289096
Drug: Poor communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor communication with poor treatment outcome
Trial: 35856373
Drug: AS-600 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS-600 (600 mg of NAC + 80 mg of propolis)
Trial: 35856373
Drug: AS-1,200 (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS-1,200 (1,200 mg of NAC + 160 mg of propolis)
Trial: 34663491
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1-g loading dose over 10 minutes, then a 3-g maintenance dose over 24 hours)
Trial: 35317983
Drug: Video group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video group (watched educational video twice)
Trial: 32193660
Drug: Audio-visual-directed exercise
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audio-visual-directed exercise training (DVD), thrice-weekly sessions of 15 min for 12 weeks
Trial: 34802036
Drug: Hypothermia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia treatment
Trial: 35718621
Drug: Intervention H
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention H (High): targeted CPB flow 3.0 L/min/m2 and mean arterial pressure (MAP) 80 mmHg
Trial: 35718621
Drug: Intervention N
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention N (Normal): targeted CPB flow 2.4 L/min/m2 and MAP 65 mmHg
Trial: 35621864
Drug: Evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140 mg subcutaneously within 24 h and 2 weeks after PCI
Trial: 35621864
Drug: Pitavastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (2 mg/day) alone
Trial: 36075591
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human tumor necrosis factor receptor-antibody type II fusion protein, 25 mg subcutaneously, injected once on every Monday and Friday for 3 weeks (6 injections total).
Trial: 33206228
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acids (KIDIMN)
Trial: 32747743
Drug: Intraarticular vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular vancomycin powder (1 g) applied before wound closure
Trial: 32847423
Drug: SIBP-01 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIBP-01 (6 mg•kg-1 intravenous dose)
Trial: 32847423
Drug: Herceptin® (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herceptin® (6 mg•kg-1 intravenous dose)
Trial: 34618684
Drug: AMY-101 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMY-101 (0.1 mg/site) administered via intragingival injections on days 0, 7, and 14
Trial: 34618684
Drug: AMY-101 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMY-101 (0.1 mg/site) administered via intragingival injections